RRC ID 88794
著者 Nakajima A, Arzamasov AA, Sakanaka M, Murakami R, Kozakai T, Yoshida K, Katoh T, Ojima MN, Hirose J, Nagao S, Xiao JZ, Odamaki T, Rodionov DA, Katayama T.
タイトル In vitro competition with Bifidobacterium strains impairs potentially pathogenic growth of Clostridium perfringens on 2'-fucosyllactose.
ジャーナル Gut Microbes
Abstract Fortifying infant formula with human milk oligosaccharides, such as 2'-fucosyllactose (2'-FL), is a global trend. Previous studies have shown the inability of pathogenic gut microbes to utilize 2'-FL. However, the present study demonstrates that the type strain (JCM 1290T) of Clostridium perfringens, a pathobiont species often more prevalent and abundant in the feces of C-section-delivered infants, exhibits potentially pathogenic growth on 2'-FL. The expression of genes for α-toxin, an activator of NLRP3 inflammasome, and ethanolamine ammonia-lyase, a factor responsible for the progression of gas gangrene, was significantly upregulated during 2'-FL assimilation compared to growth on lactose. However, colony-forming unit of C. perfringens JCM 1290T markedly decreased when co-cultivated with selected strains of Bifidobacterium, a taxon frequently detected in the breastfed infant gut. Moreover, during co-cultivation, the expression of virulence-related genes, including the gene for perfringolysin O - another activator of NLRP3 inflammasome - were significantly downregulated, while the lactate oxidation genes were upregulated. This can occur through two different mechanisms: direct competition for 2'-FL between the two organisms, or cross-feeding of lactose, released from 2'-FL by C. perfringens JCM 1290T, to Bifidobacterium. Attenuation of α-toxin production by the selected Bifidobacterium strains was observed to varying extents in 2'-FL-utilizing C. perfringens strains clinically isolated from healthy infants. Our results warrant detailed in vivo studies using animal models with dysbiotic microbiota dominated by various types of C. perfringens strains to further validate the safety of 2'-FL for clinical interventions, particularly on vulnerable preterm infants.
巻・号 17(1)
ページ 2478306
公開日 2025-12-1
DOI 10.1080/19490976.2025.2478306
PMID 40102238
PMC PMC11956901
MeSH Bacterial Proteins / genetics Bacterial Proteins / metabolism Bacterial Toxins / genetics Bacterial Toxins / metabolism Bifidobacterium* / growth & development Bifidobacterium* / metabolism Calcium-Binding Proteins Clostridium perfringens* / genetics Clostridium perfringens* / growth & development Clostridium perfringens* / metabolism Clostridium perfringens* / pathogenicity Coculture Techniques Feces / microbiology Gastrointestinal Microbiome Humans Infant Infant Formula / chemistry Lactose / metabolism Milk, Human / chemistry Trisaccharides* / metabolism Type C Phospholipases / genetics Type C Phospholipases / metabolism
リソース情報
一般微生物 JCM1290 JCM3816 JCM3817 JCM3818 JCM1217 JCM7052 JCM7054 JCM7056 JCM1192 JCM7016 JCM7019 JCM7020 JCM1209 JCM1254 JCM1255 JCM7002 JCM1210 JCM1222 JCM1272 JCM11344